|
Rituximab Biosimilar Market Opportunity Analyzed in New Research Report at …
PR Web (press release) In this report “Therapy Class Overview: Rituximab biosimilar – http://www.reportsnreports.com/reports/269204-therapy-class-overview-rituximab-biosimilar.html ”, we have analyzed the market opportunity of rituximab biosimilar. What one would get if buy … |
|
Gilead halts leukaemia study on positive results
PMLiVE The trial – known as Study 116 – is comparing idelalisib plus Roche/Biogen Idec’s Rituxan (rituximab) to rituximab alone in patients unsuitable for treatment with conventional chemotherapy. At an interim analysis, the combination was found to have a … Gilead Stops Cancer Drug Trial Early On Positive ResultsNASDAQ UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic …Benzinga Gilead stops leukaemia drug trial earlyPharmaTimes MarketWatch all 21 news articles » |
|
Gilead stops leukaemia drug trial early
PharmaTimes The safety profile of the drug was also found to be “acceptable and consistent with prior experience” when combing it with rituximab in previously treated CLL. Norbert Bischofberger, Gilead’s R&D chief, said the firm is pleased that idelalisib has … |
Gilead Stops Cancer Drug Trial Early On Positive ResultsNASDAQGilead said an interim analysis of the trial showed patients taking idelalisib plus rituximab with better progression-free survival compared to those receiving rituximab alone. The company s…
StreetInsider.com (subscription)After-Hours Stock Movers 10/9: (ACUR) (ENZN) (CHTP) Higher; (CTXS) (RT …StreetInsider.com (subscription)This DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficac…
|
Gilead Ends Study of Leukemia Treatment Early After Positive Interim Results
NASDAQ It demonstrated ” highly statistically significant efficacy” in patients receiving the treatment receiving idelalisib plus rituximab compared with those receiving rituximab alone, the company said. The company said it told the Food and Drug … |
Gilead Sciences, Inc. (GILD): Gilead Sciences +3% AH on strong leukemia drug …Seeking Alpha… not fit for chemotherapy will be stopped early based on an analysis showing highly statistically significant efficacy for the primary endpoint of progressi…
UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic …BenzingaThis DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free su…
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia …Wall Street JournalThis DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progres…
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia …MarketWatchThis DMC recommendation is based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-fre…